paget's%20bone%20disease
PAGET'S BONE DISEASE
Paget's bone disease, also known as osteitis deformans, is characterized by a significant increase in bone resorption and turnover in localized parts of the skeleton causing enlargement and thickening of the bone that is disordered and architecturally unstable.
The prevalence increases with age, with men and women affected equally.
Genetic factors and/or viral infection may play a role in the etiology.
May affect one bone (monostotic) or several bones (polyostotic).
By decreasing frequency, involved bones may include pelvic bone and sacrum, spine, skull and femur, tibia, humeri and clavicles.

Paget's%20bone%20disease Signs and Symptoms

Definition

  • Paget’s bone disease, also known as osteitis deformans, is characterized by a significant increase in bone resorption and turnover in localized parts of the skeleton causing enlargement and thickening of the bone that is disordered and architecturally unstable

Signs and Symptoms

Signs and Symptoms

  • Asymptomatic for a long period of time before signs and symptoms occur
  • Bone or joint pain is the most common symptom
  • Bone enlargement or bone deformity (eg skull enlargement, bowing of long bones)
    • Pelvis and tibia are one of the most commonly affected bones

Risk Factors

  • Prevalence increases with age, with men more commonly affected than women
  • Genetic factors and/or viral infection may play a role in the etiology
  • May affect one bone (monostotic) or several bones (polyostotic)
  • By decreasing frequency, involved bones may include pelvic bone and sacrum, spine, skull and femur, tibia, humeri and clavicles

Pathophysiology

  • Affected bone specimen (via biopsy) shows an evolution of skeletal lesions that starts as increased bone resorption by enlarged osteoclasts, followed by an increased osteoblastic activity producing a high rate of bone formation which results in deposition of a structurally abnormal bone
  • Late "burn out" phase, is an abnormal bone cell activity, which has markedly reduced and chaotic lamellar bone interspersed with woven bone
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 3 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.